
Sign up to save your podcasts
Or


In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial.
The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
By European Association of Urology3.7
33 ratings
In this podcast interview recorded at ASCO GU25, UROONCO bladder cancer chief editor Dr. Benjamin Pradere talked to Dr. Nadine Houede from CHU Nîmes, Hospital Caremeau in France, on the results of the iNDUCT trial.
The iNDUCT trial is a phase II trial evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. Dr. Houede discusses the rational, the results and next steps.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

322 Listeners

504 Listeners

55 Listeners

39 Listeners

98 Listeners

83 Listeners

284 Listeners

38 Listeners

58 Listeners

2 Listeners

87 Listeners

55 Listeners

13 Listeners

0 Listeners

14 Listeners